Search Within

Kin Tse

Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. GSK Faculty (3)
  5. Advanced Practice Providers (2)
  6. Biostatistics Service (2)

More Groups

People
  1. Howard Scher (5)
  2. Michael Morris (4)
  3. Karen Autio (3)
  4. Lewis Kampel (3)
  5. Ana Maria Molina (2)
  6. Emily Carbone (2)

More People

Years
  1. 2018 (1)
  2. 2017 (1)
  3. 2016 (2)
  4. 2011 (1)
  5. 2010 (1)
Publications
  1. Journal of Clinical Oncology (5)
  2. Urologic Oncology: Seminars and Original Investigations (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. Elsevier Inc. (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)
    Meeting Abstract

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Vaishampayan, U. N.; Shevrin, D. H.; Harrison, M. R.; Tagawa, S. T.; Milowsky, M. I.; Graff, J. N.; Beer, T. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
    Journal Article

    Milowsky, M. I.; Galsky, M. D.; Morris, M. J.; Crona, D. J.; George, D. J.; Dreicer, R.; Tse, K.; Petruck, J.; Webb, I. J.; Bander, N. H.; more...
    Urologic Oncology: Seminars and Original Investigations (2016)

    Fulltext@MSK | Save
  • Clinicopathologic findings in Jamaican men with prostate cancer
    Meeting Abstract

    Kampel, L. J.; Tse, K.; Joseph, M.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Fluorodeoxyglycose (FDG) PET as an outcome measure for metastatic prostate cancer
    Meeting Abstract

    Morris, M. J.; Fox, J. J.; Dennis, E. R.; Tse, K.; Flatts, E.; Heller, G.; Jia, X.; Schoder, H.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save